Mid-Atlantic Region III Core Center for Federally Funded HTCs

A national network of more than 140 Hemophilia Treatment Centers (HTCs) is supported and funded by the Maternal and Child Health Bureau (MCHB) of the Health Resources and Services Administration (HRSA) and the Centers for Disease Control and Prevention (CDC). HTCs are specialized health care centers staffed by a team of doctors, nurses, social workers, physical therapists and other health professionals with expertise in the treatment of bleeding disorders.

HTCs nationwide are divided into eight HRSA regions and 10 CDC regions, each of which is operated by a Core Center. The Core Centers receive funding from the CDC and HRSA; the CDC grant is administered by the American Hemostasis and Thrombosis Network (ATHN). This funding is distributed among the 140 HTCs through the Core Centers. These grants allow centers to collaborate to improve care and outcomes, create standards, partner to provide education and training to HTC healthcare professionals and staff, and to participate in surveillance to prevent complications of bleeding and clotting disorders. The region also works with consumers of health care, their families, community-based organizations, and other support networks to ensure awareness about bleeding disorders and their management and make education available to both consumers and the public.

About Mid-Atlantic Region

The Mid-Atlantic Region III consists of 16 HTCs in Pennsylvania, Delaware, Maryland, Virginia, West Virginia and the District of Columbia. Previously located at The Children’s Hospital of Philadelphia (CHOP) from 2009 to 2023, the Mid-Atlantic Region’s Core Center was transitioned to Lehigh Valley Health Network (LVHN) with the appointment of LVHN’s J. Nathan Hagstrom, MD, as Regional Director in 2023. The Core Center works to ensure that individuals with hemophilia and other bleeding disorders and their families have access to appropriate hematologic, genetic, and other medical expertise and information in the context of a medical home model that provides family-centered, culturally sensitive, high-quality and comprehensive care.

As a Core Center, LVHN oversees the services provided by the Mid-Atlantic Region’s HTCs and collaborates with the MCHB and CDC to improve treatment and support for people with hemophilia and other inherited bleeding and clotting disorders. Mid-Atlantic Region HTCs are a valuable resource at the local, regional and national level for information about bleeding disorders.

Contact Mid-Atlantic Region III Core Center

J. Nathan Hagstrom, MD, the Regional Director (RD), can be reached at 484-862-3131.

Lisa Maiale-Howell, LCSW, the Regional Administrator (RA), can be reached at 267-426-5586. 

Mid-Atlantic Region III Hemophilia Treatment Centers

Mid-Atlantic Region III consists of HTCs in Pennsylvania, Delaware, Maryland, Virginia, West Virginia, and the District of Columbia. View locations.